Jump to content

FGI-104

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by KolbertBot (talk | contribs) at 13:22, 1 November 2017 (Bot: HTTP→HTTPS (v475)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

FGI-104
Legal status
Legal status
Identifiers
  • 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H30ClN3O3
Molar mass492.008 g·mol−1
3D model (JSmol)
  • c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO

FGI-104 is the name for a family of chemical compounds that act as broad-spectrum antiviral drugs, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus. Compound R19 is the most preferred compound listed in the patent covering this family.[1][2][3]

Mechanism

The FGI-104 family of compounds act by inhibiting the protein TSG101, which transports newly replicated viruses to the exterior of an infected cell, and is required by many viruses to reinfect other cells. In pre-clinical studies FGI-104 has been shown to protect mice from Ebola virus disease.[1][4]

See also

References

  1. ^ a b http://www.ajtr.org/812004A.html Jan 2009 "FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection"
  2. ^ Michael Kinch, Michael Goldblatt. Methods of inhibiting viral infection. Patent WO 2009/091435
  3. ^ De Clercq E. "A Cutting-Edge View on the Current State of Antiviral Drug Development." Med Res Rev. 2013 Mar 11. doi: 10.1002/med.21281. PubMed link
  4. ^ Janeba Z. Development of Small-Molecule Antivirals for Ebola. Medicinal Research Reviews November 2015, 35(6):1175-1194. doi: 10.1002/med.21355